Advanced Liver Cancer Treatment Developed By This Biotech Company
A New Hope in the Fight Against Advanced Liver Cancer: Can-Fite's Namodenoson Achieves Remarkable Results.
In an era where medical advancements are breaking boundaries, a new development has given hope to those battling advanced liver cancer. Can-Fite BioPharma Ltd., an Israeli biopharmaceutical company, announced that a patient treated with their drug Namodenoson showed a complete response and an impressive overall survival of 6.9 years.
Namodenoson: A Promising Treatment
The patient, who was suffering from advanced hepatocellular carcinoma (HCC), the most common type of primary liver cancer, was treated with Namodenoson as part of a Phase II clinical trial. The results were extraordinary – the patient achieved a complete response and survived for 6.9 years. This is significant considering that the median survival for advanced HCC patients is less than a year.
Namodenoson is an orally bioavailable drug designed to target the A3 adenosine receptor (A3AR), which is overexpressed in cancer cells. By targeting this receptor, Namodenoson inhibits the growth of cancer cells and induces apoptosis, the process of programmed cell death.
The Significance of This Breakthrough
This breakthrough is a beacon of hope for patients with advanced liver cancer. Liver cancer is the fourth leading cause of cancer-related deaths worldwide, and current treatment options are limited and often come with severe side effects.
The impressive results achieved with Namodenoson may pave the way for a new, more effective treatment option. As Dr. Pnina Fishman, CEO of Can-Fite, stated, "These results are encouraging and provide the basis for further development of Namodenoson as a potential treatment for liver cancer".
While the results from this single patient need to be interpreted with caution, they provide a promising glimpse into the potential efficacy of Namodenoson in treating advanced liver cancer.
The Road Ahead
Can-Fite's achievement with Namodenoson is undoubtedly a significant step forward in the fight against liver cancer. However, further studies will be needed to confirm these results in larger patient populations.
The journey is far from over, but one thing is certain: Can-Fite's commitment to developing innovative treatments for cancer is making a difference in patients' lives.
Disclaimer: This article includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: